Check out our latest Validated PK & ADA Methods List Read about Veeda's partnership with Ahammune Biosciences for first in human studies Watch our Latest Symposium on Immuno-centric Approach to Biosimilar and Vaccine Development Check out our Assay List (Method Library)

Bring your Complex Generic Products to Market Quickly and Effectively with Our Comprehensive Capabilities

Leveraging the Veeda Edge to
handle your BA/BE Studies

Our services include

Study Design & Study Conduction

Project Management

Medical Affairs

Bio Analytical Services

Data management & Biostatistics

Regulatory Guidance

Tackle the Complexity of your Generic Drug
Development with Veeda

Our experience of conducting BA/BE studies in healthy volunteers across different dosage forms

Vaccine

Injectable Emulsion

Injection

Rectal/ Vaginal Suppository/ Foam

Nasal Spray

Inhalation

Transdermal System/Patches

Topical Product

Syrup

Oral

Capusle & Tablet

Glucose Clamp

End-to-End support with robust clinical strategy for your next trial on Complex Generics

Demonstrating the bioequivalence, safety, and efficacy of a complex generic drug can be challenging. Veeda Clinical Research has the experience and expertise to expedite your reach to the market.

Proven Expertise to handle your Complex
Generics Studies

Inhalation Bioequivalence Studies

12 BA/BE Long Acting Injectable Studies

Studies including 810 Glucose Clamps

Transdermal patch & Suppositories/Rectal Product Studies

Veeda has been a partner in supporting 505(b)(2) applications with ~45 studies experience with various clients

Types of Generic Drugs

A generic drug is an equal substitute or alternative for its brand-name counterpart as it has the same strength and provides the same clinical benefit as the branded drug. The USFDA defines a generic drug as medication developed and produced to have the API, dosage form, strength, therapeutic use, route of administration, and quality performance characteristics, same as an already marketed branded drug.
ANDA stands for Abbreviated New Drug Application. Pharmaceutical companies need to submit an ANDA to the regulatory authority for review & approval to market a generic drug. The ANDA contains information that proves that the generic medicine is safe and effective as the brand drug.
FDA defines 505(b)(2) application as a New Drug Application (NDA) containing complete reports of investigations of safety and effectiveness in which some of the required information for regulatory approval comes from studies that the applicant has not conducted or for which the sponsor/applicant has not obtained a right of reference or use. 505(b)(2) candidates include an NME, New active ingredient, New dosage form, New combination, New indication, New formulation, previously marketed but without an approval & Rx to OTC (Previously approved drug changed to OTC or changes to existing OTC product).

Request a Call Back

Submit your details and we’ll be in touch shortly. You can also email us if you would prefer.